Announcement on behalf of Amaran of not Distributing Dividends of 2021

Announcement on behalf of Amaran that the BOD resolved to convene the 2022 Annual General Shareholders' Meeting

OBI-999 ”Conjugated Biological Molecules, Pharmaceutical Compositions and Methods“ Was Granted By Taiwan Intellectual Property Office

Announcement of the expiration of the Company's 2022 cash capital increase call period and the issuance of stocks

AEMPS of Spain revokes previous approval for the Active Cancer Immunotherapy, OBI-822, to proceed to Phase III Clinical Trial

Announcement of the Company's full receipt of cash capital increase in 2022 and the reference date of capital increase

Announcement of not Distributing Dividends in 2021

The Company's Board of Directors resolved to convene the 2022 Annual General Shareholders' Meeting

Announcement of 2021 Consolidated Financial Statements were approved by the Board of Directors

Supplemental announcement-subscription rights to the cash issue forfeited by directors of the Company reaching 50% and made to specific persons